- Home
- PBFS vs DBVT Comparison
PBFS vs DBVT Comparison
Compare PBFS & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBFS
- DBVT
- Stock Information
- Founded
- PBFS 1889
- DBVT 2002
- Country
- PBFS United States
- DBVT France
- Employees
- PBFS N/A
- DBVT N/A
- Industry
- PBFS Banks
- DBVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PBFS Finance
- DBVT Health Care
- Exchange
- PBFS Nasdaq
- DBVT Nasdaq
- Market Cap
- PBFS 287.0M
- DBVT 250.5M
- IPO Year
- PBFS N/A
- DBVT N/A
- Fundamental
- Price
- PBFS $12.31
- DBVT $10.80
- Analyst Decision
- PBFS
- DBVT Buy
- Analyst Count
- PBFS 0
- DBVT 4
- Target Price
- PBFS N/A
- DBVT $14.81
- AVG Volume (30 Days)
- PBFS 35.7K
- DBVT 26.3K
- Earning Date
- PBFS 05-09-2025
- DBVT 07-29-2025
- Dividend Yield
- PBFS N/A
- DBVT N/A
- EPS Growth
- PBFS 27.31
- DBVT N/A
- EPS
- PBFS 0.80
- DBVT N/A
- Revenue
- PBFS $88,641,000.00
- DBVT $3,497,000.00
- Revenue This Year
- PBFS N/A
- DBVT $1,700.53
- Revenue Next Year
- PBFS N/A
- DBVT $535.67
- P/E Ratio
- PBFS $15.62
- DBVT N/A
- Revenue Growth
- PBFS 21.19
- DBVT N/A
- 52 Week Low
- PBFS $10.07
- DBVT $2.21
- 52 Week High
- PBFS $12.65
- DBVT $12.78
- Technical
- Relative Strength Index (RSI)
- PBFS 65.28
- DBVT 58.42
- Support Level
- PBFS $11.91
- DBVT $10.53
- Resistance Level
- PBFS $12.65
- DBVT $11.33
- Average True Range (ATR)
- PBFS 0.40
- DBVT 0.76
- MACD
- PBFS 0.06
- DBVT 0.14
- Stochastic Oscillator
- PBFS 92.80
- DBVT 65.90
About PBFS Pioneer Bancorp Inc.
Pioneer Bancorp Inc is involved in providing banking services. These services include Personal services such as Checking, Savings, eBanking Cards, and Business services such as Business Deposit and operating Accounts, Business eBanking, and Business loans. Some of the other services of the company include Government Banking, Wealth Management, Benefits Consulting and Insurance.
About DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.